FDA Approves First Treatment For MCT8 Deficiency

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA approved Emcitate (tiratricol) oral suspension on September 28, 2026, the first treatment for MCT8 deficiency (Allan-Herndon-Dudley syndrome). The drug lowers excess thyroid hormone levels in the blood by entering cells without relying on the broken MCT8 transporter.

The U.S. Food and Drug Administration on September 28, 2026 approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The approval marks the first time the FDA has authorized a therapy for this very rare genetic disease, which primarily affects males and previously had no FDA-approved treatment option.

Emcitate is indicated to treat peripheral thyrotoxicosis — excess thyroid hormone levels in the blood that cause symptoms such as rapid heart rate, increased blood pressure and adverse metabolic effects — in patients with MCT8 deficiency. The drug was approved for Egetis Therapeutics US Inc. after receiving Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, as well as Priority Review.

The effectiveness of Emcitate was evaluated in two clinical studies spanning patients from infants to adults: an international, multi-center, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. According to the FDA, patients treated with Emcitate across both studies had reductions in excess thyroid hormone levels in the bloodstream and improvements in cardiovascular and metabolic symptoms, including systolic blood pressure and heart rate.

Emcitate is taken once daily as a liquid suspension, either by mouth or through a feeding tube for patients who have difficulty swallowing. The most common side effects reported were diarrhea, vomiting, rash and excessive sweating. The FDA cautioned that patients taking another thyroid medication should consult their healthcare provider before starting Emcitate, as the two should not be used together, similar to guidance accompanying other recent FDA-authorized health technologies like the first wearable device that monitors ketone and blood sugar levels.

A First Option for a Devastating Disease

Until this approval, families affected by MCT8 deficiency had no FDA-approved treatment for the condition. “Until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option,” said Marina Zemskova, M.D., Deputy Director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research. “Emcitate’s approval reflects the FDA’s deep commitment to patients with rare conditions who are in need of meaningful treatment options.”

Many patients with MCT8 deficiency experience debilitating effects, including the inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism. While Emcitize addresses the elevated blood thyroid hormone levels and associated cardiovascular and metabolic symptoms, the approval gives clinicians and families a regulated, studied therapy where none previously existed. The FDA said the approval reflects its dedication to patients with rare genetic diseases, many of whom have serious unmet medical needs.

How the Faulty Transporter Causes Harm

MCT8 deficiency is a rare genetic disorder that primarily affects males. It is caused by a faulty gene that provides instructions for making the MCT8 transporter, a protein responsible for carrying thyroid hormone into the brain. Because thyroid hormone cannot cross the blood-brain barrier without the transporter, the brain receives too little of the hormone while excessive levels build up in the bloodstream — producing the peripheral thyrotoxicosis that Emcitate is approved to treat.

“The challenge in treating MCT8 deficiency has always been that the protein needed to deliver thyroid hormone into cells is the one that isn’t working,” said Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research. “This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”

“This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”

— Hylton V. Joffe, M.D., MMSc, Director, Office of Cardiology, Hematology, Endocrinology, and Nephrology, FDA Center for Drug Evaluation and Research

Effects on Neurologic Symptoms Unknown

The FDA’s announcement describes improvements in blood thyroid hormone levels and cardiovascular and metabolic symptoms, such as systolic blood pressure and heart rate. The press release does not state that Emcitate improves the neurologic and developmental features of MCT8 deficiency — such as intellectual disability, limited speech, or the inability to walk or sit independently — and it is not yet clear from the available announcement whether the drug affects those outcomes. The underlying genetic defect is not corrected by the therapy; tiratricol bypasses the broken transporter rather than repairing it.

Additional details not specified in the announcement include pricing, insurance coverage and exact launch timing for Emcitate in the United States.

Rollout and Longer-Term Study Ahead

Egetis Therapeutics US Inc. is expected to bring Emcitate to market in the United States, with timing and pricing details to be confirmed by the company. Because MCT8 deficiency is extremely rare, treatment will likely be coordinated through specialist endocrinology and genetics centers experienced with the condition.

Patients currently taking other thyroid medications should talk to their healthcare provider before starting Emcitate, as the drugs should not be used together, according to the FDA. Consumers with questions can contact the FDA at 888-INFO-FDA. Longer-term data on the drug’s effects, including any impact on developmental outcomes, may emerge from continued follow-up studies and post-approval monitoring.

Key Questions

What is Emcitate approved to treat?

Emcitate (tiratricol) is FDA-approved to treat peripheral thyrotoxicosis — excess thyroid hormone in the blood causing symptoms such as rapid heart rate and elevated blood pressure — in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.

How does Emcitate work if the MCT8 transporter is broken?

According to the FDA, the active ingredient tiratricol can enter cells on its own without relying on the defective MCT8 transporter, which lowers the elevated thyroid hormone levels in the bloodstream.

What were the most common side effects in clinical studies?

The most common side effects were diarrhea, vomiting, rash and excessive sweating. Patients taking another thyroid medication should consult their healthcare provider first, as the two should not be combined.

Does Emcitate cure MCT8 deficiency?

No. Emcitate treats the symptoms related to excess thyroid hormone in the blood. It does not correct the underlying genetic defect, and the FDA’s announcement does not claim improvement in neurologic or developmental outcomes.

How is Emcitate taken?

It is taken once daily as a liquid suspension, either by mouth or through a feeding tube, making it accessible for patients with a wide range of abilities.

Source: primary